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Central nervous system control of inflammation-induced muscle
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Background and aims: Skeletal muscle catabolism is a co-morbidity of many
chronic diseases and is the result of systemic inflammation. While direct
inflammatory cytokine action on muscle promotes atrophy, non-muscle sites
of action for inflammatory mediators are less well described. We sought to
demonstrate that inflammatory signaling limited to the central nervous system
induces muscle catabolism.
Methods: Interleukin-1 beta (IL-1β) was injected centrally at doses that esti-
mate pathophysiological concentrations found during illness. Control injections
of the same dose were given peripherally. Both acute and chronic studies were
performed in animals with pharmacological and surgical blockade of glucocor-
ticoid signaling. Molecular and pathological analysis of muscle was performed.
Results: We have demonstrated that central nervous system-delimited IL-1β
signaling alone potently evokes a catabolic program in muscle, rapidly induc-
ing atrophy. This effect is dependent on hypothalamic–pituitary–adrenal
(HPA) axis activation, as CNS IL-1β-induced atrophy is abrogated by adre-
nalectomy or pharmacological blockade of glucocorticoid signaling. Micro-
array analysis also demonstrated that a glucocorticoid-responsive gene
expression patternispresentinthemuscleofmultiplemodelsofinflammatory
muscle atrophy. Adrenalectomy also blocks the atrophy program in response
to systemic inflammation, demonstrating that glucocorticoids are requisite for
this process. When circulating levels of corticosterone are clamped at a level
equivalenttothoseproducedunderinflammatoryconditions,profoundmuscle
wasting occurs.
Conclusions: Together, these data suggest that a significant component
of inflammation-induced muscle catabolism occurs indirectly via a
relay in the central nervous system.
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Gαi2 signaling promotes skeletal muscle hypertrophy, myoblast differ-
entiation and regeneration via PKC- and HDAC- dependent pathways
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Skeletal muscle atrophy results in increased loss of function and
mortality. The signaling pathways downstream of G protein-coupled
receptors (GPCRs) that are able to block atrophy have not been well
studied. In this study, we demonstrate that activation of the hetero-
trimeric guanine nucleotide—binding protein (G protein) Gαi2 induces
skeletal muscle hypertrophy. Gαi2 is required for hypertrophy induced
by lysophosphatidic acid, which activates a Gαi-linked GPCR. A
constitutively active mutant of Gαi2 results in myotube growth, char-
acterized by increased protein synthesis and enhanced fusion. Gαi2
activates p70S6 kinase and inhibits GSK3β, thereby activating the pro-
differentiation NFAT transcription factor. Gαi2 activity is dependent on PKC
signaling, since PKC inhibitors block the effects induced by Gαi2, whereas
activatedPKCαinduceshypertrophy.Gαi2canalsoinhibitatrophycausedby
the cachectic cytokine TNFα, and thereby blocks the upregulation of the
atrophy-inducing E3 ubiquitin ligase MuRF1 via inhibition of the HDAC/
Myogenin pathway. We also found that Gαi2 activation enhances muscle
regeneration and causes a switch to oxidative fibers; the fiber-type switch
is coincident and perhaps caused by an upregulation of PGC-1β.T h i s
study thus identifies a previously undiscovered skeletal muscle hypertro-
phy and differentiation pathway, and links Gαi2 to the recently identified
HDAC/myogenin/MuRF1 atrophy pathway, indicating that receptors that
act through Gαi2 represent potential targets for preventing skeletal muscle
wasting.
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Down regulation of TWIST-1 and its target, the miR 199/214 cluster, in
human myocardium of patients with dilated cardiomyopathy results in
increased proteasome activity
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Background: TWIST-1 is a transcription factor that has been described
to regulate the microRNA (miR) 199/214 cluster during development.
Genetic disruption of TWIST-1 resulted in a cachectic phenotype and
early death of the knockout mice. This might be connected to the
activity of the ubiquitin-proteasome system (UPS), as miR 199a has
been suggested to regulate the ubiquitin E2 ligases Ube2i and Ube2g1.
A loss of cardiomyocyte diameter and left ventricular mass is regularly
seen in dilated cardiomyopathy.
Methods: Cardiac tissue from explanted heart of 40 patients with dilated
cardiomyopathy and 20 rejected donor hearts were analysed for protein
expression of TWIST-1and its inhibitor Id-1, MuRF-1 and MAFbx, the
expression of miR 199a, 199b and 214, as well as the activity of the UPS by
using specific flurogenic substrates in an enzyme kinetics assay.
Results: TWIST-1 was downregulated by 43% compared to donors (p0
0.003), while Id1 expression was unchanged. This resulted in a reduced
expression of miR199a (−35.2%, p00.107), miR 199b (−33%, p00.042)
and miR 214 (−41%, p00.015) compared to donor hearts. An increased
peptidylglutamyl-peptide hydrolysing activity (p<0.0001) was observed in
the UPS, while the chymotrypsin-like and trypsin-like activities were un-
changed (both p>0.2). The protein level of the rate-limiting ubiquitin E3-
ligasesMuRF-1andMAFbxwereup-regulatedcomparedtodonors(p00.006
and 0.038, respectively).
Conclusion: In summary, the TWIST-1/miR199/214 axis is downregulated
in dilated cardiomyopathy, which is likely to play a role in the increased
activity of the UPS. This may contribute to the loss of cardiac mass during
dilatation of the heart.
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Does the exposition to GSM electromagnetic waves induce a no thermal
effect on a fast-twitch skeletal muscle, the “edl” in rats?
Wiam Ramadan, Sara Shouaib, Aida Ibreik, Hassane Khachfe, Fatima Jbai,
Wissam H. Joumaa (Laboratory of Environmental Physio-Toxicity (Phy-
ToxE), ER 017, EDST, Lebanese University, Faculty of Sciences, Nabatieh,
Lebanon)
One of the important challenges developed in the last decades and
could affect health is the population exposure to electromagnetic
waves (EMW), particularly the ‘Global System of Mobile Communi-
cation signals’, GSM signals. These GSM signals are emitted from
many sources as like cell phones and base stations antenna. Our study
investigates the effects of EMW radiation emitted from GSM mobile
phones antenna (frequency at 900 MHz, Eeff025 V/m) on extensor dig-
itorum longus (edl) muscle myofibrillar proteins. Results show that ani-
mals body weight was not affected by 6 weeks of continuous 24-
h exposure, but edl absolute muscle mass was increased by 10.5%
(control: 0.1744±0.00252, exposed: 0.1927±0.00291, n012, p<0.05).
Since myofibrillar proteins content is directly proportional to muscle
mass, protein dosage using the Bradford technique was performed and
protein concentration was calculated in mg/g of muscle. An increase
by 59% in edl myofibrillar protein content after the period of expo-
sure was observed (control 20.11±1.59, exposed 31.97±2.81, n012, p
<0.05). The analysis of MHC isoforms by SDS-PAGE as already
described by Talmadge et al. shows an increasing by 431.54% in MHC I,
35.08% in MHC IIa a decreasing by 16.34% in MHC IIb without a significant
modification in the percentage of expression of MHC IIx/d (n012 and p<
0.05).Thus,thisstudyshowsthat6weeksofcontinuouswhole-bodyexposure
to EMW can induce a no thermal effect in myofibrillar proteins of fast-twitch
mammalian skeletal muscles.
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Role of lipases in cancer-associated cachexia
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Cancer-associated cachexia is a multi-organ syndrome associated
mainly with gastrointestinal and lung cancer. It is characterized by
progressive loss of body weight, reduced muscle strength, and loss of
adipose tissue as well as skeletal muscle mass. We evaluated the role
of lipases, adipose triglyceride lipase (ATGL), and hormone sensitive
lipase (HSL) in the initiation and progression of cancer-associated
cachexia using two tumor models, Lewis ung carcinoma and B16
mlanoma in wildtype (wt), ATGL knockout, and HSLknockout mice.
Cachexia was evaluated based on various systemic parameters, body
weight, and specific organ weights as well as body composition using
NMR and MRI techniques. While wt mice lost ~90% white adipose
tissue (WAT) and ~40% skeletal muscle (m. gastocnemius) weight due
to tumor progression, ATGL knockout mice retained the tissue depots
in spite of similar tumor development. HSL knockout mice showed an
52 J Cachexia Sarcopenia Muscle (2012) 3:51–68attenuated cachectic phenotype in comparison to wildtype. This
resulted in significant body weight decrease in tumor-bearing wt and
HSL knockout mice but ATGL knockout mice remained protected
from cachexia. Although serum lipolytic factors, IL-6, ZAG, and
TNF-alpha levels were similarly enhanced in tumor mice of all gen-
otypes, WAT from ATGL tumor-bearing mice showed reduced lipoly-
sis compared to tumor-bearing wt mice. Increased proteosomal and
caspase 3/7 activities were observed in tumor-bearing wt mice which
are attenuated in tumor-bearing lipase knockout mice. Interestingly,
total triglyceride hydrolase activity and ATGL activity in particular in
WAT of cancer patients showed a significant negative correlation with
patient body mass index. Enzyme activities in non-cancer patients
failed to show any such correlation. The results propose that both
ATGL and HSL plays instrumental role in the progression of cancer-
associated cachexia and hence they might represent attractive targets for
drugs development.
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A in vitro model for skeletal muscle force and atrophy, myotransducer
Toshihiro Chikanishi, Kei Segawa, Atsushi Baba, Yoshiaki Azuma, Kei
Yamana (Musculoskeletal Research Department, Pharma-ceutical Discovery
Research Laboratories/TEIJIN Pharma Limited, Tokyo, Japan)
Background and aims: Skeletal muscle atrophy is characterized by a
decrease in muscle mass and force. In the drug discovery for muscle
atrophy, muscle hypertrophy or increased muscle mass can be easily
monitored using cellular or animal model rather than force measure-
ment. However, since previous researches have implicated that muscle
force measurement is important for monitoring the effect of treatment
in muscle atrophy, we tried to establish in vitro muscle force mea-
surement system, myotransducer.
Methods: Electro pulse stimulation (EPS) of C2C12 cells was used for in
vitro muscle force model. C2C12 cells were seeded on collagen membranes
and differentiated to myotube (myosheet) then EPS (0.5 V, 0.5 Hz) was
applied until maximal tetanus force (max-force) of myosheet reached to
stable state. IGF-1 and dexamethasone (DEX) were added in order to
induce for hypertrophy or atrophy and time course of max-force was
monitored.
Results: After 10-days EPS treatment, IGF-1 myosheets showed hypertro-
phic feature and its max-force was significantly higher than control. DEX
induced myotube disruption and its max-force was diminished. This was
accompanied by increased mRNA expression of atrogin-1, MuRF-1 and
Cbl-b. When EPS loading was decreased (0.5~0.05 V), max force was
also reduced in a voltage intensity dependent manner, but IGF-1 treatment
had still higher max force than control. Moreover, when EPS reloaded at
higher level, max-force of IGF-1 myosheets was rapidly recovered up to
initial level before voltage lowering started. At the end point of EPS,
atrogin-1 and MuRF-1 mRNA expressions were suppressed by IGF-1
treatment. These results are similar to IGF-1 treatment on in vivo muscles
atrophy.
Conclusions: Our in vitro system, myotransducer, could detect differ-
ence of muscle force by voltage loading (hypertrophy) and unloading
(atrophy), and drug treatments (IGF-1 and glucocorticoid). These
results suggest that myotransducer may be useful to estimate muscle
force in vivo.
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Ghrelin secretion and anxiety in a rat model of anorexia–cachexia
induced by methotrexate chemotherapy
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Background and aims: Peripheral acylated ghrelin has orexigenic and
anxiolytic effects, but its expression in the brain and putative roles are
uncertain. Here, we studied if peripheral and central ghrelin expressions are
altered in chemotherapy-associated anorexia–cachexia.
Methods: Preproghrelin and GOAT mRNA were assayed in the stomach,
hypothalamus and amygdala and plasma acyl- and des-acyl-ghrelin were
measured in Sprague–Dawley rats treated with methotrexate (MTX,
2.5 mg/kg, SC for 3 days). Forced-swim (FST) and elevated plus maze
(EPM) tests and tissues sampling were performed at day 5 after first MTX
injection, corresponding to the maximal decrease in food and water intakes
and a loss of 25% of body weight. Control rats received PBS; the EPM test
was done in a separate series of rats.
Results: Preproghrelin mRNA expression levels were lower in the stomach
but increased in the hypothalamus of MTX rats. GOAT mRNA was de-
creased in the stomach and amygdala but not in the hypothalamus of MTX
rats. Plasma levels of acyl- and des-acyl ghrelin did not differ significantly
from controls but acyl-/des-acyl ghrelin ratios was lower in MTX rats. No
significant differences in FST were observed between MTX and control
rats, but fewer entries in open and central zone of the EPM were found in
MTX rats.
Conclusions: These data show that the hypothalamic preproghrelin gene
expression isincreasedduringMTX-induced anorexia. Considering activation
of hypothalamic neurosecretory vasopressin neurons in MTX-treated rats
(Hamze-Sinno M. et al.; Physiol Behav, 2010), and immunohistochemical
detectionof ghrelininmagnocellularneurons(ownunpublishedresults),these
data suggest that both acyl- and des-acyl-ghrelin can be secreted from the
hypothalamus into the systemic circulation in order to compensate loss of
gastric ghrelin and/or to counteract dehydration. However, the lower rates of
acylation ofsystemic ghrelin in MTX rats maycontribute to anorexia–cachex-
ia and increased anxiety.
Supported by EU INTERREG IVA 2 Seas Program (7-003-FR_TC2N) and
a collaborative grant with Kagoshima University, Japan
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Endothelial function and circulating angiogenic cells in Fabry disease
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Background: Fabry disease is an X-chromosomal recessive deficiency of
the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), which cata-
lyzes the hydrolytic cleavage of the terminal galactose from globotriaosyl-
ceramide (GL-3). This results in an accumulation of GL-3 in a variety of
cells such as endothelial cells, smooth muscle cells, and cardiomyocytes
leading to functional impairment. A majority of patients develop end-stage
kidney disease depending on dialysis treatment. This is associated with the
malnutrition-inflammation atherosclerosis syndrome, progressive cachexia,
and endothelial dysfunction. Enzyme replacement therapy can prevent or
attenuate onset of cardiovascular complications.
Methods: We investigated the impact of Fabry disease on the biology of
circulating angiogenic cells (CACs) and endothelial function. Twenty-six
patients with untreated Fabry disease, 16 patients after 12 months of
enzyme replacement therapy (ERT), and 26 healthy controls were investi-
gated. Endothelial function was assessed by the EndoPat 200 device. CAC
numbers were assessed by flow-cytometry, CAC function by a modified
Boyden chamber assay.
Results: Fabry patients showed an impaired endothelial function, which nor-
malized after enzyme replacement therapy. Fabry patients displayed increased
numbers, but impaired function of CACs. Immunofluorescence and electron
microscopy identified an excessive accumulation of GL-3 in Fabry diseased
CACs. Enzyme replacement therapy attenuated CAC dysfunction in Fabry
patients via a reduction in GL-3 accumulation in vitro and in vivo. SiRNA-
mediated knockdown of alpha-Gal A in healthy CACs impaired their migratory
capacity underlining a key function of this enzyme in CAC function.
Conclusions: Fabry patients show a dysfunction of circulating CAC and an
impairment of endothelial function. Enzyme replacement therapy improves
CAC and endothelial function and thus may attenuate development of cardio-
vascular/kidney disease and finally cachexia development in the long-term in
this patient population.
2–20
The miRNA-212/132 family regulates cardiomyocyte size and
autophagy
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Purpose: Growth control of cardiomyocytes is of major importance for
diseases such as cardiac hypertrophy and cardiac wasting. MiRNAs are novel
master regulators of gene expression, but their role in such processes is not
entirely clear and never has been investigated systematically.
Methods and results: Here, we performed a functional miRNA library
screen in cardiomyocytes and show the microRNA (miRNA)-212/132
family to regulate hypertrophy and autophagy. Hypertrophic stimuli lead
to the upregulation of miR-212 and miR-132 expression in cardiomyo-
cytes, which are both necessary and sufficient to drive the hypertrophic
growth of cardiomyocytes. MiR-212/132 null mice are protected from
pressure-overload-induced heart failure, whereas cardiomyocyte-specific
overexpression of the miR-212/132 family leads to impaired autophagic
activity, pathological cardiac hypertrophy, heart failure, and finally in-
creased lethality in mice. Mechanistically, both miR-212 and miR-132
directly target the anti-hypertrophic and pro-autophagic FoxO3 transcrip-
tion factor and overexpression of these miRNAs leads to hyperactivation
of pro-hypertrophic calcineurin/NFAT signalling and impaired autopha-
gic response upon starvation. Pharmacologic inhibition of miR-132 by
antagomir injection rescues cardiac hypertrophy and heart failure in
mice, offering a possible therapeutic approach for cardiac failure.
Conclusions: The miRNA-212/132 family plays a dominant role in the
development of cardiac hypertrophy and heart failure and serves as a novel
therapeutic relevant target.
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Angiotensin II upregulates Pp2cα and inhibits AMPK signaling and
energy balance leading to skeletal muscle wasting
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Background and aims: Several diseases, including congestive heart
failure and chronic kidney disease are characterized by elevated an-
giotensin II (Ang II) and muscle wasting. Ang II causes muscle
54 J Cachexia Sarcopenia Muscle (2012) 3:51–68wasting by reducing appetite and enhancing catabolism, but little is
known about the effects of Ang II on muscle metabolism and energy
stores. Muscle-specific overexpression of insulin-like growth factor 1
(IGF-1) prevents Ang II wasting despite the ability of Ang II to
impair upstream IGF-1 signaling. In mice overexpressing IGF-1 in
skeletal muscle (MLC-IGF-1), the serine/threonine kinase 5′-adenosine
monophosphate-activated protein kinase (AMPK), which functions as
a sensor of cellular energy status, is activated by 62%. We hypothe-
sized that Ang II induces muscle wasting by inhibiting AMPK sig-
naling and altering energy balance, and that AMPK activation
mediates the protective effects of IGF-1 against Ang II wasting.
Methods: We infused 1,000 ng/k/min Ang II or sham infused FVB
mice or MLC-IGF-1 mice for 7 days ± the pharmacological AMPK
activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR)
and measured ATP, muscle weight; AMPK, AKT expression and
phosphorylation; E3 ubiquitin ligase expression.
Results: Ang II infusion in mice reduced gastrocnemius muscle weight
by 26% and depleted ATP by 74%. Furthermore, Ang II upregulated
the protein phosphatase PP2Cα by 2.6-fold and reduced AMPK phos-
phorylation and signaling in muscle. Importantly, muscle-specific
overexpression of IGF-1 and AICAR each blocked Ang II-induced
PP2Cα upregulation, restored AMPK activity to levels of controls,
and reversed Ang II-mediated ATP depletion and muscle wasting.
Moreover, AICAR activated Akt and inhibited Ang II-induced
increases in E3 ubiquitin ligase expression.
Conclusions: These results demonstrate critical roles for energy depletion
and AMPK inhibition in Ang II-induced muscle wasting, and demonstrate a
role for AMPK activation in IGF-1 mediated rescue from Ang II wasting.
These findings suggest a therapeutic potential for AMPK activators in
diseases characterized by muscle wasting.
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Signaling in the heart of rats with cancer cachexia compared
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Background: Cachexia is a common co-morbidity in cancer and chronic
heart failure (CHF) and increases the mortality of patients. It is well
established that CHF and chemotherapeutics in cancer lead to an impaired
heart function due to ventricular remodeling, but it is not known if the
tumor itself affects the heart. Here, we compared the effects of cancer
cachexia-induced to myocardial infarction-induced cardiac alterations in
signaling.
Study design and methods: We used the AH-130 hepatoma model
(13 days) as a model for cancer cachexia and the LAD model (56
and 210 days) to induce cardiac cachexia. In all studies, we assessed
the body weight, body composition, cardiac function and quality of
life. At the end of the studies, we sacrificed the animals and measured
the weight of the organs. Finally, we looked for apoptosis, necrosis
and fibrosis in the heart using fluorogenic and Luminex assays.
Furthermore, we analysed atrophic proteins and anabolic signaling
pathways by Western Blot.
Results: Myocardial infarction of rats caused an impaired heart function
without the induction of true cachexia. We found neither apoptosis nor
an increase in catabolic signaling, but a rise in the anabolic signaling in
the heart. The rat cancer model caused severe cachexia with a strongly
impaired cardiac function. There was a 58% loss of LV mass due to an
increased catabolism (UPS-System), more apoptosis (increased activity of
caspase-3 and -6), necrosis and a downregulation of the anabolic
signaling (Akt, 4EBP1, p70S6K).
Conclusion: Myocardial infarction did not cause cachexia but led to the
development of heart failure. The hepatoma animal model as a model for
cancer cachexia severely impaired the cardiac function and led to body and
cardiac wasting.
*p<0.05 vs Sham, **p<0.01 vs Sham, ***p<0.001 vs Sham.
Table. Results of studies
Day 13 Day 56 Day 210
Sham Tumor Sham LAD Sham LAD
Δ Body weight vs baseline (%) 23.4±2.06 −23±1.08 *** 71.6±3.51 66.3±2.99 142±8.49 178±4.42 ***
Δ Lean mass vs baseline (%) 21.7±1.36 −24.8±1.15 *** 12.13±1.28 12.42±1.10 NA NA
Weight of heart (mg) 787±15.93 466±12.14 *** 1,132±19.61 1,278±45.3 ** 1,220±32.7 1,582±56.4 ***
LV EF (%) 79.7±1.50 50.5±1.39 *** 63.3±1.18 30.74±1.86 *** 72.9±4.85 37.1±1.52 ***
Caspase-3 activity in the heart
(nmol/mg/min)
29.3±3.70 99.2±28.9 * 221±76.9 200±33.1 74.9±11.53 81.6±6.88
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Atrophy-mechanisms are up-regulated in cardiac tissue of patients
with advanced dilated cardiomyopathy
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Dilated cardiomyopathy (DCM) is the most common form of cardiomyop-
athy and patients suffer from typical symptoms of heart failure. Recently, it
was shown that wasting of cardiac mass may play a crucial role in heart
failure.
The aim of the study was to examine which hypertrophic and atrophic
signalling pathways are influenced in cardiac tissue of patients with ad-
vanced DCM in comparison to a control group (donors).
Therefore, protein expression of total and phosphorylated Akt (pAkt),
p70S6K, 4E-BPI, GSK3-α/β, Myostatin, and LC-3-I/II as well as p62 as
autophagosomal-acting proteins were analysed in septum of 20 heart donors
and 41 recipients with advanced DCM. Furthermore, apoptotic activity in
the septum was measured by fluorometric caspase assay.
Total Akt but notphosphorylated Akt (active) issignificantly (P<0.05) down-
regulated in patients with DCM in comparison to donors. There is also a
significantdown-regulation of downstream targets of Akt-like phosphorylated
p70S6K (active; P<0.01), phosphorylated 4E-BPI (inactive; P<0.001), and
phosphorylated GSK3β (P<0.05) and GSK3α (P<0.001; inactive) which all
might lead to inhibition of protein synthesis and cardiac tissue growth. Fur-
thermore, an up-regulation of myostatin (P<0.001) has been observed. The
caspase-3activity wassignificantlyelevated (P<0.001)whereasthecaspase-6
activity remained unchanged.Hence, apoptotic processes might be elevated in
cardiac tissue of DCM patients compared to control group. Finally, autophagy
might also influence the process of wasting in cardiac tissue because the
expression of LC-3 II was increased (P<0.001) whereas the expression of
p62 remained unchanged in comparison to the control group.
The results show a down-regulation of hypertrophic pathways as well
as an up-regulation of atrophic pathways in cardiac tissue of DCM
patients compared to donors. This might lead to a loss of cardiac
tissue and therefore contribute to the progression of heart failure and
its symptoms.
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Introduction: Total and direct serum bilirubin have been shown to be
predictive for decreased survival in patients with chronic heart failure
(CHF). Considering liver function tests, cachectic CHF patients fre-
quently present with hypoalbuminemia. However, levels of bilirubin
and other liver function parameters in cardiac cachexia have not been
investigated yet.
Methods: We prospectively investigated 112 non-cachectic CHF patients
(age 66.5±0.9 years; left ventricular ejection fraction [LVEF] 31.2±0.7;
NYHA class 2.4±0.1; peak VO2 16.7±0.5 mL/kg/min, body mass index
[BMI] 28.7±0.5 kg/m
2), 15 cachectic CHF patients (age 66.0±2.7 years;
LVEF 27.9±2.0; NYHA class 2.8±0.1; peak VO2 12.0±1.3 mL/kg/min,
BMI 22.9±0.9 kg/m
2), and 31 healthy control subjects (age 61.4±2.2 years;
LVEF 59.5±0.8; peak VO2 31.2±1.8 mL/kg/min, BMI 24.8±0.5 kg/m
2).
Diagnosisofcachexiawasmadeaccordingtocurrentconsensusbasedcriteria.
We measured direct and indirect bilirubin, albumin, gamma-glutamyl trans-
ferase (GT), alkaline posphatase (AP), alanine aminotransferase (ALAT),
aspartate aminotransferase (ASAT), high-sensitive C-reactiveprotein (hsCRP)
and in a subgroup of 77 patients mid-regional pro-adrenomedullin (MR-
proADM) in blood. Hepatic vein diameter, central venous pressure (CVP)
and systolic pulmonary arterial pressure (PAP) were estimated by abdominal
sonography and echocardiography, respectively.
Results: Cachechtic patients had higher serum levels of direct bilirubin, GT,
AP and lower serum levels of albumin compared to non-cachectic patients and
controls, indicating altered liver function (direct bilirubin 0.39±0.09 vs 0.21±
0.01 vs 0.15±0.02 mg/dl; GT 128.6±31.3 vs 69.9±7.3 vs 25.1±2.6 U/L; AP
111.3±15.6 vs 71.8±3.0 vs 56.4±2.5U/L; albumin 33.2±0.9 vs 36.9±0.4 vs
38.0±0.5 g/L, all ANOVA p≤0.002). Cachectic patients, compared to non-
cachectic, had lower transaminase levels; however, within the normal range
(ALAT 19.3±3.1 vs 27.1±1.2, p<0.005; ASAT 23.8±2.2 vs 29.6±1.0, p0
0.024). Levels of total and indirect bilirubin were similar in cachectic and non-
cachectic patients versus controls. Considering all patients, higher levels of
direct bilirubin, GT and AP correlated with CVP (direct bilirubin r00.58; GT
r00.50; AP: r00.52, all p<0.0001) and PAP (direct bilirubin r00.43, p0
0.0002; GT r00.40, p00.0004; AP r00.35, p00.002). Furthermore, levels of
GTand AP correlated with greater hepatic vein diameter (r00.49, p00.008 and
r00.55, p00.002). Higher direct bilirubin in these patients correlated positively
with prognostic markers such as hsCRP (r00.24, p<0.01), MR-proADM (r0
0.4, p00.0006), and NYHA class (r00.32, p00.0004).
Conclusion: Markers of cholestatic liver damage are elevated in
patients with cardiac cachexia and correlate with indices suggestive
of right heart congestion. This indicates a role of liver congestion in
elevation of these cholestatic markers in cardiac cachexia as a clinical
feature of CHF.
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Introduction: Liver dysfunction is a frequent co-morbidity in CHF
patients. Blood supply to the liver in these patients has not been investigat-
ed yet. We hypothesized that arterial blood flow to the liver gradually
declines in patients with CHF with worsening of the clinical status and
correlates with abnormal liver function tests.
Methods: We prospectively investigated 15 CHF patients in New York
Heart Association (NYHA) Class I–II (age 64.4±2.7 years; left ventricular
ejection fraction [LVEF] 33.2.9±1.8; peak VO2 18.0±1.2 mL/kg/min, body
mass index [BMI] 28.5±1.5 kg/m
2) and 18 patients in NYHA III–IV (age
68.2±2.1 years; LVEF 25.5±2.3; peak VO2 13.6±0.9 mL/kg/min, BMI
26.2±1.0 kg/m
2). Eight of the patients in NYHA class III–IV were cachec-
tic according to current consensus based criteria (age 65.7±4.1 years; LVEF
22.9±3.4; peak VO2 12.3±1.8 mL/kg/min, BMI 23.8±0.8 kg/m
2). We
measured blood flow in the hepatic artery and portal vein by Doppler
sonography. LVEF was assessed by echocardiography. Postischemic fore-
arm blood flow was measured by venous occlusion plethysmography. Liver
function tests were measured in serum.
Results: Patients with advanced CHF (NYHA III–IV) showed lower
systolic and diastolic blood flow in the hepatic artery compared to
patients with milder CHF (NYHA I–II) (Table 1). As expected,
patients in NYHA III-IV had a higher pulsatility index of portal vein,
reflective of higher systemic and liver congestion. However, blood
flow volume in the portal vein did not differ significantly between
both groups. Among all CHF patients, cachectic patients had the
lowest systolic and diastolic flow in hepatic artery (50.5±9.7 vs
84.1±8.2 mL/min, p00.03 and 68.9±18.2 vs 107.3±11.7 mL/min,
p00.096). In CHF patients, we found a positive correlation between
systolic flow in the hepatic artery and LVEF (r00.47, p00.01). Dia-
stolic flow in the hepatic artery was positively correlated to postis-
chemic forearm blood flow (r00.42, p00.02), a parameter reflective
of vascular resistance and endothelial dysfunction. Furthermore, sys-
tolic and diastolic blood flow in the hepatic artery correlated nega-
tively with levels of alkaline phosphatase (p<0.05, p00.26),
suggesting a role of reduced arterial flow in liver dysfunction.
Conclusion: Arterial blood supply to the liver is reduced in patients with
advanced CHF and may contribute to cholestatic liver damage in these
patients.
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Background: The symptoms fatigue, weight loss, impaired exercise capac-
ity and dyspnea are typically present in patients with chronic heart failure
(CHF) as well as in those with colorectal cancer (CRC). We hypothesize
that in patients with CRC neuroendocrine activation and autonomic dys-
function may contribute to the typical symptoms of CHF by decoupling of
physiologic pathways.
Table 1 Cardiac and hepatic sonographic measurements in patients grouped by NYHA class
Mean±standard error
Factor All NYHA I–II (n015) NYHA III–IV (n018) p value
LVEF (%) 29.2±1.2 31.2±0.7 25.5±2.3 0.008
Hepatic arterial FV (mL/min) 77.6±7.9 92.6±1.4 64.4±10.2 0.075
Hepatic arterial systolic FV (mL/min) 75.1±7.0 94.6±10.8 58.1±7.1 0.007
Hepatic arterial diastolic FV (mL/min) 97.1±10.2 122.9±15.4 74.5±11.2 <0.02
Portal vein diameter (cm) 0.81±0.02 0.79±0.03 0.82±0.03 NS
Portal vein FV (mL/min) 306.2±24.9 319.7±46.4 294.9±25.5 NS
Pulsatility index of portal vein 0.42±0.03 0.33±0.03 0.49±0.05 <0.02
Abbreviations: NS not significant, LVEF left ventricular ejection fraction, FV, blood flow volume
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10 years, 27 male, body mass index [BMI] 28±4 kg/m
2,h e m o g l o b i n
[Hb] 13.2 g/dl), 28 patients with CRC (60±12 years, 11 male, BMI: 25±
4, Hb: 12.0) and 40 healthy controls (CON 60±11 years, 26 male, BMI 25±
3, Hb 14.4). An echocardiogram and a 24 h-ambulatory-holter ECG were
obtained from each subject to assess parameters of heart function and heart
rate variability (HRV). The HRV is a measure of autonomic function. Peak
oxygen uptake (Peak VO2) and breathing efficiency (BE) were obtained to
assess exercise capacity by cardiopulmonary exercise testing
(spiroergometry).
Results: Patients with CHF and CRC displayed significantly impaired
autonomic function as compared to controls when measured as time
domain analysis by the standard deviation of normal RR intervals
(SDNN, CHF 116.9±29.8, CRC 122.5±32.6, CON 142.6±36.8 ms,
both p<0.05 vs. CON). A significantly reduced SDNN-Index was also
observed in CRC patients (CRC 41.5±14, CON 54±16 ms, p00.002).
In the frequency domain analysis, patients with CHF and CRC had a
significantly decreased low frequency power (CHF 421±361, CRC
430±303, CON 742±429 ms
2, both p< 0 . 0 5v s .C O N )a n da ni m -
paired ratio of low-to-high frequency spectra power (CHF 2.6±1.1,
CRC 3.8±1.9, CON 5.1±2.2 ms
2, both p< 0 . 0 5v s .C O N ) .I nC R C ,
patients the very low frequency power was also significantly reduced
(CRC 1,353±900 vs. CON 2,268±1,274 ms
2, p00.003). Peak VO2
and BE were significantly reduced in CHF and CRC patients com-
pared to controls (CHF 17±4/36±7, CRC 20.6±5/32±6, CON 28±
6m l / m i n / k g / 2 8 ± 4L ,a l lp<0.05 vs. CON). The left ventricular
ejection fraction was significantly reduced in patients with CHF (35±
8%) and in patients with CRC (59±4%) as compared to controls (63±
5%, both p<0.05 vs. CON).
Conclusions: Decreased HRVas an indication for predominant sympathetic
activation, limited exercise capacity, and disturbance of heart function are
present in CHF patients as well as in CRC patients. This may influence
quality of live and survival. Further studies are required.
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Introduction: Chronic heart failure (CHF) is characterized by reduced
circulatory blood flow due to low cardiac output, sympathetic activation
and impaired vasodilator capacity. Impaired tissue perfusion may occur as
well in the intestinal vascular bed. This hypoperfusion may contribute to
intestinal dysfunction. Intestinal arterial blood flow and clinical symptoms
have not yet been studied in patients with and without cardiac cachexia.
Methods: We investigated 65 patients with CHF (LVEF 30±1%, peak VO2
15.2±0.6 mL/kg/min, BMI 28.2±0.6) and 26 control subjects of similar age
and gender (LVEF 64±2%, peak VO2 27.3±1.4 mL/kg/min, BMI 26.1±0.8).
Twelve of the patients were cachectic (LVEF 25±2%, peak VO2 12.7±
1.2 mL/kg/min, BMI 25.4±1.5). Intestinal peak systolic blood flow was
calculated from peak velocity and vessel diameter of the mesenteric arteries
(MA) and celiac trunk (CT) using high-resolution ultrasound and Doppler
sonography. We measured bowel wall thickness by transcutaneous sonogra-
phy. Gastrointestinal symptoms were evaluated by gastrointestinal symptom
rating scale.
Results: CHF patients showed a lower mean systolic blood flow in the
intestine supplying arteries superior and inferior MA and CT compared to
control subjects(351±22 vs. 522±37 mL/min, and 55±4 vs. 93±7 mL/min
and 419±33 vs. 672±89 mL/min, all p<0.004). The same applied to the
peak systolic blood flow in these three main vessels which was again lower in
CHF patients compared to controls (1.9±0.1 vs. 2.6±0.2 L/min, and 0.29±
0.02 vs. 0.47±0.038 and 1.9±0.1 vs. 2.9±0.4 L/min, all p<0.004). Cachectic
CHF patients showed lowest mean systolic blood flowin superior and inferior
MA and CTcompared to non-cachectic patients and control subjects (259±51
vs. 378±24 vs. 522±22, 47±11 vs. 57±4 vs. 93±7, and 287±59 vs. 441±36
vs. 672±89 mL/min, p00.0007). In superior MA, inferior MA and CT,
patients compared to controls had lower mean diastolic blood flow, too (266
±27 vs. 307±31 mL/min, p<0.04; 34±3 vs. 51±6 mL/min p<0.006; and 338±
27 vs. 582±84 mL/min, p<0.004). Cachectic patients showed lowest mean
diastolic flow in celiac trunk compared to non-cachectic patients and controls
(260±69 vs. 352±29 vs. 582±84, p<0.05). Impaired intestinal blood flow in
CHF was in accord with greater bowel wall thickness suggestive for bowel wall
edema in cachectic and non-cachectic patients compared to controls (all p<
0.0007). Patients compared to controls had more murmurs from the intestine,
burping, feelings of repletion and flatulences (all p<0.05). Burping was more
oftenincachecticvs.non-cachectic patients (5/11 vs. 8/46, p<0.05). CHF
patients with abdominal discomfort had lower mean systolic flow in
celiac trunk (274±36 vs. 480±38 mL/min, p00.02).
Conclusion: Impaired tissue perfusion occurs as well in the intestinal
vascular bed in CHF. This is most pronounced in cachectic patients. This
mesenteric malperfusion may contribute to intestinal hypoxia and may
hence contribute to gastrointestinal dysfunction in patients with cardiac
cachexia.
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The myogenic potential is reduced in experimental cancer cachexia
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Background and aims: Cancer cachexia is a syndrome characterized by
loss of skeletal muscle proteins, depletion of lipid stores and hormonal
perturbations. Muscle wasting is mainly due to a hypercatabolic response;
58 J Cachexia Sarcopenia Muscle (2012) 3:51–68however, a reduced myogenic potential has been proposed to contribute to
the onset of cachexia.
Methods: Balb-c mice were divided into controls (C) and tumor bearers
(TB); the latter inoculated s.c. with 5×105 C26 carcinoma cells. The day
after, mice received an i.m. injection of 1.2% BaCl2 in the tibialis anterior.
They were sacrificed at day 14 of tumor growth. The tibialis was excised
and stored at −80°C. Muscle cross-sectional area (CSA) was evaluated after
Hematoxylin & Eosin (H&E) staining, while the expression of PAX7, a
transcription factor expressed by proliferating satellite cells, and Myogenin
(Myog), a late differentiation marker, were analyzed by immunofluores-
cence (IF) and Western blotting (WB).
Results: When compared to C, C+BaCl2 mice showed a reduced CSA, and
centro-nucleated fibers were visible by H&E staining. The percentages of
PAX7+ and of Myog+ cells increased in IF and an increment in both these
proteins was detected by WB. The growth of C26 tumor causes in mice a
marked decrease of bothmusclemass andCSA, associated with accumulation
of PAX7+ and Myog+ cells. When the muscle of TB is injured by BaCl2, the
following regenerative process is far from being complete. Indeed, compared
to BaCl2-treated C, H&E staining in TB injured muscles showed a further
reduction in CSA, presence of small centro-nucleated fibers and accumulation
of interstitial cells; IF analysis revealedanincreasedpercentage of PAX7+and
Myog+ cells.
Conclusions: The accumulation of PAX7 in TB muscles suggested a
defective myogenic potential. Muscle injury in C26 mice severely affected
the regenerative program, likely because of a marked inflammatory re-
sponse. Further studies are needed to clarify the relevance of satellite cell
accumulation to the onset of muscle wasting and to unravel the role of pro-
inflammatory environment.
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Background: Male cancer patients suffer from fatigue, sexual dysfunction,
and decreased functional performance and muscle mass. These symptoms
are also seen in men with hypogonadism and/or inflammatory conditions.
However, the relative contribution of testosterone and inflammation to
symptom burden has not been well established.
Aims: To determine the prevalence of hypogonadism and the relationship
between testosterone, inflammation, and symptom burden in male cancer
patients.
Methods: This cross-sectional study enrolled patients from a tertiary-care
center. Patients included males with cancer cachexia (CC, n045), cancer
without cachexia (CNC, n050), and non-cancer controls (n045). Total testos-
terone (TT), bioavailable testosterone (BT), C-reactive protein (CRP), and
interleukin (IL)-6 were measured in plasma. Functional performance was
assessedbytheECOG(EasternCooperativeOncologyGroup)andKarnofsky
performance scales (KPS). Sexual function was evaluated by IIEF (Interna-
tional Index of Erectile Function).
Results: Prevalence of hypogonadism was >70% in CC. TTwas lower in CC
compared to CNC (p<0.05). Also, CC had lower BT, grip strength, IIEF
scores, appendicular lean body mass (aLBM), and fat mass; and higher IL-6
and CRP compared to controls (p≤0.05). ECOG and KPS were lower in CC
and CNC compared to controls (p≤0.05). On multiple regression analysis, TT
and CRP predicted most symptoms in cancer patients.
Conclusions: Cancer cachexia patients have higher inflammation and lower
testosterone, grip strength, functional status, erectile function, fat mass, and
aLBM.Inflammationandhypogonadismareassociatedwithheaviersymptom
burden in this population. Interventional trials are needed to determine if
testosterone replacement and/or anti-inflammatory agents benefit cancer
patients.
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Background and aims: Cancer cachexia occurs in a majority of patients
suffering from incurable solid tumours. It is characterized by loss of muscle
tissue and a combination of reduced food intake and catabolism such as
systemic inflammation.Recentwork,also of patients having cardiaccachexia,
suggests the importance of neuro-hormonal mechanism in cachexia. Prelimi-
nary empirical studies document autonomic nervous system dysfunction in
cancer cachexia; further understanding of its components may guide cachexia
treatment.
Methods: Cancer cachexia patients with no current anti-cancer treatment
were eligible. Autonomic testing consisted of a time domain-based analysis
of heart rate variability under the paradigms of breathing (at rest and deep
breath) for the evaluation of the parasympathetic cholinergic (PC) nervous
system, blood pressure changes following valsalva manoeuvre (qualitative
and quantitative evaluation of the sympathetic noradrenergic (SN) system)
and active standing (orthostasis) with the Finometer Pro (FP) device
(Finapres Medical Systems, The Netherlands). Sympathetic skin response
was done for the evaluation of the sympathetic cholinergic (SC) system.
Nerve conduction studies were additionally performed.
Results: Thirteen patients (five NSCLC, three GI, and six other tumours)
were included (median age, 66 years; gender, 11 male). Eleven of 13
patients showed pathological results in two categories of which SN (n0
6), SC (n06) and orthostatic hypotension (n05) were equally affected. Of
note, only one patient showed pathological results in PC category. Eight of
13 patients additionally showed subclinical large fibre polyneuropathy, only
two of them being previously treated with neurotoxic chemotherapy.
Conclusion: In this small cohort of patients with advanced solid tumours,
autonomic dysfunction occurs frequently in the sympathetic but rarely in
the parasympathetic cholinergic nervous system. Subclinical polyneurop-
athy was not associated with this finding. Our results contradict recent
publications showing an impairment of parasympathetic function in male
patients with advanced solid cancer.
Acknowledgments: this work is supported by the Eagle and Miltreytz-
Foundations
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Background: Cachexia, fatigue, and dyspnea are frequently observed
among patients with pancreatic cancer (PCA). We hypothesize that the
development of the cancer fatigue syndrome is at least partly due to
cardiovascular pertubations with the consequence of decreased exercise
capacity and reduced quality of life.
Methods: We prospectively studied cardiovascular parameters in 96
patients with PCA (age 58.9±0.9 years; mean±SE; 60 male; body mass
index [BMI] 23.2±0.4 kg/m
2; hemoglobin [Hb] 11.3±0.2 g/dl) and 74
healthy controls (CON 59.7±1.3 years; 40 male; BMI, 26.2±0.5 kg/m
2;
Hb 13.9±0.2 g/dl) in exercise capacity using symptom-limited exercise test,
cardiacfunction using echocardiography, bodycompositionusing dual energy
X- ray absorptiometry, heart rate variability using 24-h ECG, and peripheral
blood flow using venous occlusion plethysmography in patients and controls.
In addition, we studied, serum levels of tumor necrosis factor-a (TNF-α),
interleukin-6, and TNF-receptor 1/2 (TNF-R1/2) in a subgroup of 42 patients
with PCA and 22 CON. Cachectic and non-cachectic patients were compared.
Results: No significant difference was detected between patients and CON in
terms of sex, age, and systolic function. Patients with PCA compared to CON
displayed impaired exercise capacity (peak VO2, 21.1±0.6 vs. 27.2±1.0 mL/
min/kg), less total lean mass (68.6±1.3 vs. 78.4±1.6 kg), increased resting
blood flow in the leg (4.3±0.4 vs. 2.8.3±0.2 mL/100 mL/min), impaired
autonomicfunction (SDNN24h, 100.3±30.8 vs. 134±37.5ms),andelevated
pro-inflammatorymarkers(IL-6:5.2±0.8vs.1.8±0.2pg/mL;TNF-R1:1,828
±132 vs. 1,245±69 pg/mL; TNF-R2: 2,811±143 vs. 2,018±120 pg/mL; all p<
0.05).Autonomicdysfunctionincachecticpatientswasevenworsethaninnon-
cachectic patients (SDNN 24 h 94.6±4.9 vs. 109.9±4.5 ms, p00.03).
Conclusions: Reduced exercise capacity, less lean mass, autonomic dys-
function, increased resting blood flow, and elevated proinflammatory
markers are present in patients with PCA. Further studies are required.
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Background: Cachexia, fatigue, and dyspnea are frequently seen in
patients with non-small cell lung cancer (NSCLC). We hypothesize that
the development of the cancer fatigue syndrome is at least partly due to
cardiovascular perturbations with the consequence of decreased exercise
capacity and reduced quality of life.
Methods: To investigate the cardiovascular parameters, we prospectively
studied 42 patients with NSCLC (age, 60±9 years; mean±SEM, 26 male;
body mass index [BMI], 24.8±4.7 kg/m
2; hemoglobin (Hb), 12.2±1.9 g/dl)
and 41 healthy controls (CON 61±11 years, 26 male; BMI 25.4±3.5 kg/m
2;
Hb, 14.4±1.0 g/dl) in exercise capacity using symptom-limited exercise test,
cardiac function using echocardiography, body composition using dual energy
X-ray absorptiometry, peripheral blood flow using venous occlusion plethys-
mography,andheartratevariabilityusing24-hECGinpatientsandcontrols.A
subgroup analysis of non-cachectic (N-CACH; n028) and cachectic (CACH)
patients (n013) was performed due to the consensus definition of cachexia.
Results: No significant difference was detected between patients and CON in
terms of sex, age, and systolic function. Patients with NSCLC displayed
impaired exercise capacity (peak VO2 in NSCLC 17.6±0.9 mL/min/kg vs.
CON28.3±1.1mL/min/kg), less total lean mass(NSCLC47.8±1.8 vs.53.3±
1.8kg),lowerpeakbloodflowinforearm(NSCLC17.4±1.0mL/100mL/min
vs.CON22.3±1.4mL/100 mL/min),and leg(NSCLC11.0±1.1 mL/100 mL/
min vs. CON 15.4±1.4 mL/100 mL/min), and impaired autonomic function
(SDNNinNSCLC 97.5±36.5msvs.CON142±36.9ms;allp<0.05).CACH
patients showed significantly impaired exercise capacity compared to N-
CACH patients (CACH 18.84±0.97 mL/min/kg vs. N-CACH 13.96±
1.4 mL/min/kg, p00.03).
Conclusions: Reduced exercise capacity, less lean mass, worse blood flow,
and autonomic dysfunction are present in patients with NSCLC. Symptoms
may be due to systemic changes like neuroendocrine activation and inflam-
mation. Further studies are required.
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C-terminal agrin fragment—a serum marker of sarcopenia?
Ruggero Fariello, Stefan Hettwer, Pius Dahinden, Jan Vrijbloed (Neurotune
AG, Bioggio, Switzerland)
Sarcopenia is characterized by loss of muscle mass and functionality at
old age. The causes of sarcopenia are subject of intensive research but
largely poorly understood. A prerequisite for successful treatment of
sarcopenia patients is the development of effective diagnosis. Various
causes for sarcopenia have been suggested, among which, on the basis
of recent data in aged animals, a crucial role of the neuromuscular
junction (NMJ), the sole link between motor neurons and muscle
fibers, has emerged. As a consequence sarcopenia is commonly referred
to as a syndrome of the NMJ. The extracellular matrix protein agrin is
essential for the formation and stabilization of NMJs. Agrin is cleaved
by the pre-synaptic protease neurotrypsin at two sites thereby losing its
NMJ-stabilizing function. Agrin cleavage by neurotrypsin frees a solu-
ble 22-kDa C-terminal agrin fragment (CAF) detectable in blood.
Clinical trials were undertaken to test the hypothesis that overactivity
of neurotrypsin as revealed by elevated levels of CAF in serum, plays a
pathogenic role in the genesis of sarcopenia. Initial normal range
studies demonstrated that in a healthy population of Swiss blood
donors, CAF is measurable in bloodwhereit shows a narrow range of values
that do not vary with aging. Based on these observations, a pilot multicenter,
non-randomized, open-label, vertical clinical study was designed. Briefly, 133
informed and consenting elderlies (>65-year-old adults) were recruited and
60 J Cachexia Sarcopenia Muscle (2012) 3:51–68assigned to a sarcopenia patients group defined according to up to date
diagnostic criteria and an aged matched control group. Elevated agrin degra-
dation occurs in a substantial subset of sarcopenia patients and can be used to
identify those patients in whom a novel pathogenic target may be therapeuti-
cally exploited. Excessive degradation of agrin by neurotrypsin leading to
fragmentation of the NMJs appears to be an important process in the patho-
genesis of sarcopenia.
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Animal model for agrin-dependent sarcopenia—the SARCO mouse
Jan Vrijbloed
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Sarcopenia is characterized by loss of muscle mass and muscle function. The
causes of sarcopenia are subject of intensive research but largely poorly
understood. A requirement to properly address diagnosis and treatment of
pathological conditions is the availability of suitable animal models. These
models should reproduce the pivotal behavioural and pathological features of
the condition they are supposed to mimic. We have recently found that levels
of a c-terminal agrin fragment (CAF), exclusively generated from agrin’s
cleavage by neurotrypsin, are significantly augmented in 40% of sarcopenia
patients. Agrin, a synaptically located protein, is a key player during initial
formation and maintenance of neuromuscular junctions (NMJs) where it
induces acetylcholine receptor assembly and aggregation. Agrin forms a
complex with LRP4, a low-density lipoprotein receptor-related protein and
MuSK, a transmembranetyrosine kinase. Oncecleavedbyneurotrypsin,agrin
is inactive leadingtodispersalofNMJs. In the cleavage process, asoluble,22-
kD CAF fragment is freed and circulates in body fluids. A transgenic mouse
overexpressing human neurotrypsin (termed SARCO) was generated (Bol-
liger, J Cell Sci, 123:3944, 2010) in order to provide an animal model of
sarcopeniatoadvanceknowledgeofthepathogenicmechanisms.Asexpected,
CAF levels in SARCO mice are elevated by a factor of 1.5 compared to the
WT. Furthermore,SARCOmice shareallthe essentialpathologicalfeaturesof
sarcopenia patients which include reduction of muscle mass, irregular fiber
sizewithcentralnuclei,selectivefiber-typelossandalteredmorphologyofthe
NMJs (Bütikhofer, Faseb J, 2011). In addition, SARCO mice are weak and
show significant motor impairment which aggravates with time. These phe-
notypesprefigureapathologicallyalteredneuromuscularsystem.TheSARCO
mouse represents a valuable model of sarcopenia and offers an ideal in vivo
approach to test possible pharmaceutical treatments aimed at this new target.
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The association between sarcopenia and sarcopenic obesity and
lipid profile in elderly men
Asta Mastaviciute
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Background: Sarcopenia is a main cause of the loss of mobility and
independence in the elderly. A combination of excess weight and reduced
muscle mass and strength is called as sarcopenic obesity. The studies of
lipid metabolism in sarcopenic obesity are limited.
Purpose: The aim of this study was to investigate serum lipid profile in
sarcopenic and sarcopenic-obese elderly men.
Methods: A cross-sectional study design was used in this study. Subjects of
this study were men (n047) aged 65 years and more. Exclusion criteria
were conditions and current use of any medication known to affect muscle
and lipid metabolism. DXA was used to measure fat mass, body fat
percentage, and lean mass (iDXA, GE Lunar). Sarcopenia was defined
condition when appendicular skeletal muscle mass divided by stature
squared was 7.26 kg/m
2 a n dg a i ts p e e dw a s> 0 . 8m / s .I nc a s eo ft h e
combination of sarcopenia and excess body fat (percentage of body fat
greater than 27%), subjects were classified as sarcopenic-obese. Blood
samples were obtained between 9 and 11 am after overnight fasting. Total
cholesterol, high-density lipoproteins, low-density lipoproteins (LDL), and
triglycerides were analyzed.
Results: Of all men investigated, 31 were sarcopenic and 16 were defined
as sarcopenic-obese. There was the weak negative association between
muscle mass and total cholesterol (r0−0.34, p00.018) and LDL (r0−0.36,
p00.012) in sarcopenic group, but in sarcopenic obesity group muscle mass
was not statistically significant associated with lipid profile.
Conclusions: Sarcopenia is associated with serum lipids: total cholesterol
and LDL. Larger cohorts of subjects studied are needed to clarify the
significance of our finding.
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Muscle-specific atrophy with aging: the AGES-Reykjavik study
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Background: Aging is associated with loss of skeletal muscle mass and
muscle attenuation (i.e., higher muscle fat infiltration). Although most
studies have previously used quadriceps muscle, muscle atrophy and atten-
uation may vary across muscle groups and may relate to the muscle
structure-function paradigm of mechanical loading/unloading.
Aims: The purpose of this study is to investigate whether with increasing
age there is differential muscle-specific atrophy and muscle attenuation in
muscles with different mechanical function.
Methods: Men (n02,214) and women (n02,997) from the Age, Gene/
Environment (AGES) Reykjavik Study, born in 1907–1935 (age range
66–96 years), and living in Reykjavik participated in this cross-sectional
study design. Muscle-specific cross-sectional areas of seven different
muscles were manually outlined from two CT images (L4/L5 and mid-
thigh). Fatty infiltration (captured by the Hounsfield’s unit (HU) of the
J Cachexia Sarcopenia Muscle (2012) 3:51–68 61muscle tissue) was calculated as the average density in each muscle.
Quadriceps, hamstring, sartorius, psoas (primary antigravity/locomotion
function) and rectus abdominis, paraspinal, and lateralis (primary postural
function) were outlined.
Results: Compared to quadriceps muscle, with increasing age, we ob-
served: (1) greater muscle mass atrophy for paraspinal and rectus in men
and women; (2) greater fatty infiltration for rectus, hamstring, paraspinal
(female only), lateralis (female only), sartorius (male only); (3) lower
muscle mass atrophy in men and women for hamstring, sartorius and psoas
(female only); (4) lower fatty infiltration for psoas; and (5) increasing total
muscle atrophy with age (i.e., sum of all muscles) with the oldest group (85
+years) having ~78% muscle mass of the youngest group.
Conclusions: Increasing age is associated with heterogeneous muscle-
specific atrophy and muscle attenuation. This may relate to the muscle
structure–function paradigm of mechanical loading/unloading (e.g., postur-
al versus antigravity/locomotion primary function). Functionally, these
results suggest a potential greater loss of mechanical muscle function for
postural muscles which may jeopardize to a greater extent older adults’
ability to carry out motor tasks involving postural control.
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Branched-chain amino acid oxidation in skeletal muscle—practical im-
portance of its modulation by glutamine and ammonia availability in
cachectic illness
Milan Holeček, Miroslav Kovařík, Luděk Šišpera (Department of Physiol-
ogy, Charles University in Prague, Faculty of Medicine in Hradec Kralove,
Czech Republic)
Background and aims: Enhanced oxidation of branched-chain amino
acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle is a
typical metabolic alteration of cachectic illness associated with acti-
vated synthesis of glutamine and development of muscle wasting. It
can be hypothesised that modulation of glutamine synthesis by reac-
tant availability may affect BCAA oxidation and protein metabolism
in skeletal muscle.
Methods: Two separate experiments were performed using male Wistar rats
in which the effect of glutamine synthesis inhibition and glutamine synthe-
sis stimulation on BCAA and protein metabolism was evaluated. In the first
study, glutamine synthesis was inhibited via alanyl-glutamine infusion in
endotoxemic and intact rats. In the second study, glutamine synthesis was
stimulated by infusion of ammonium acetate/bicarbonate mixture. Control
animals were infused by the mixture of sodium salts. The parameters of
protein metabolism and leucine oxidation were measured under steady state
conditions using L-[1-
14C]leucine infusion. Statistical comparisons were
performed using ANOVA and Bonferroni test.
Results: Infusion of alanyl-glutamine induced a decrease in plasma BCAA
levels, a decrease in leucine oxidation, and an improvement of protein
balance due to the decrease in proteolysis both in intact and endotoxemic
rats. Ammonium infusion induced an increase in ammonia and glutamine,
an increase in BCAA oxidation, a decrease in BCAA and alanine levels in
blood plasma, a decrease in whole-body protein turnover, and a decrease in
protein synthesis in skeletal muscle.
Conclusions: It is concluded that changes in glutamine synthesis induced
by alanyl-glutamine and by ammonia infusion are associated with signifi-
cant alterations in BCAA and protein metabolism. The results also demon-
strate that the cause of decreased plasma BCAA levels observed frequently
in liver cirrhosis is hyperammonemia.
Supported by Research Project MSM 0021620820.
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Objective: The objectives of this study were to determine the prevalence of
anorexia–cachexia syndrome (ACS), and to know the clinical profile, nutri-
tional status, and therapeutic approach of ACS in Spanish elderly patients.
Methodology: Thisisamulticenterepidemiologicalstudyintwophases.The
study is approved by theEthicsCommittee of HospitalGeneralde l’Hospitalet
de Llobregat (Barcelona).
The objectives of this study were: for phase A, to determine the prevalence
of ACS in elderly, according to the Evans’s criteria; and for phase B, to
describe the clinical profile of geriatric patients with ACS. The eligible
patients had met the following inclusion criteria: age >65 years; comply
with the definition of ACS according to Evans et al. (Clin Nutr 27:793–799,
2008)(at least5% loss of edema-free bodyweight in the previous12 months
or BMI below 20 kg/m
2); also meet at least three of the following criteria:
decreased muscle strength, fatigue, anorexia, low rate free-fat mass, and
biochemical abnormalities. All patients had given written informed consent.
Results: Sixty-six centers distributed for Spain participated in the study.
Four thousand fifty-three (4,153) patients were included in phase A for the
prevalence study. Twenty-four percent (24%) had weight loss >5% in the
last 12 months. Of these, 15.8% met the diagnostic Evans’s criteria for
ACS. The results in phase B were: mean age 83 years and concomitant
diseases: neoplasia (15.4%), chronic kidney disease (26.8%), COPD
(27.5%), diabetes mellitus (30.9%), and chronic heart failure (45.6%).
Nutritional status assessed by the MNA questionnaire indicated that
76.4% of patients were malnourished, 22.3% were at risk of malnutrition.
There was a positive correlation between MNA and the five criteria of
Evans. The therapeutic approach followed in these patients showed that
71% received dietary counseling, 40.5% received drug treatment, and 82%
of them were already being treated with megestrol acetate.
Conclusions: The ACS affects 15.8% of the Spanish elderly population.
The ACS is associated with chronic diseases frequent in elderly population
such as chronic heart failure, COPD, renal failure, diabetes mellitus, and
cancer. There is a positive correlation between nutritional status and the
parameters that define the Evans’s criteria of ACS, this allows concluding
that these criteria can be a useful tool in clinical practice to diagnose and
monitoring these patients. Over 80% of ACS patients with pharmacological
treatment received megestrol acetate. Under our knowledge, this is the first
study that provides data on the prevalence of SCA in the elderly, using the
criteria of Evans as a diagnostic tool.
62 J Cachexia Sarcopenia Muscle (2012) 3:51–681. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, GuttridgeD,JatoiA,
Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli
M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A,
Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin
Nutr. 2008 27:793–799
Acknowledgments: The authors thank all co-investigators for their partici-
pation in the study
Study granted by Rottapharm, S.L. (Spain)
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Plasma nesfatin-1 concentrations in restricting-type anorexia
nervosa
Marie Amitani, Kazuma Ogiso, Masako Nakano, Akihiro Asakawa, Haruka
Amitani, Miharu Ushikai, Izumi Haruta, Ken-Ichiro Koyama, Akio Inui
(Division of Psychosomatic Internal Medicine, Department of Social and
Behavioral Medicine, Kagoshima University Graduate School of Medical
and Dental Sciences, Kagoshima, Japan)
Background and aims: Restricting-type anorexia nervosa (AN-R) is an
eating disorder characterized by severe emaciation with marked caloric reduc-
tion secondary to an inordinately strong desire to lose more weight, and
pervasive fearoffatness, resulting in sustainedlow weight. Althoughprevious
studieshaveshownthatchangesinfeedingregulatorypeptidessuchasghrelin
are associated with anorexia, little is known about the relationship between
AN-R and nesfatin-1, a novel 82-amino acid peptide identified as a satiety
peptide derived from nucleobindin-2. Therefore, we measured the plasma
nesfatin-1 levels in AN-R patients to investigate its role in AN-R.
Methods: Fifteen women participated in this study; seven patients with
AN-R and eight age-matched healthy controls (average BMI, 13.0±0.3 vs.
21.6±0.5, respectively). After overnight fasting, blood samples were
obtained from each subject. The levels of nesfatin-1, acyl ghrelin, and
des-acyl ghrelin in the samples were measured.
Results: Plasma nesfatin-1 levels were significantly lower in AN-R group
than in control group (P<0.05). Plasma acyl ghrelin and des-acyl ghrelin
levels were significantly higher in AN-R group than in control group (P<
0.01 and P<0.05, respectively).
Conclusions: Our result indicates that nesfatin-1 is involved in nutrition
status.
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The FRAIL scale was developed by the International Academy of Nutrition
and Aging as a simple diagnostic tool for frailty. The scale includes five
components: fatigue, resistance, ambulation, illness, and loss of weight.
FRAIL scale scores range from 0 to 5 (1 point for each component; 00best
to 50worst) and represent frail (3–5), pre-frail (1–2), and robust (0) health
status. In a population of middle-aged adults (ages 49–65) in the African
American Health (AAH) study (N0703), cross-sectional analyses showed
that frail or pre-frail health status were associated with more instrumental
activitiesofdailyliving(IADLs)disabilities,lowershortphysicalperformance
battery scores, lower grip strength, and shorter times for the one-leg stand (all
ps<0.01) when those with any baseline deficits in activities of daily living
(ADLs) were excluded from the analyses. TNFR1 and CRP values were
elevated in pre-frail and frail individuals (ps<0.05). Being frail or pre-frail at
baseline also significantly predicted incident ADLs and mortality at 9 year
follow up (all ps<0.05). The FRAIL scale showed overlap with the Cardio-
vascular Health Study, Study of Osteoporotic Fractures, and Rockwood et al.
frail scales. The FRAIL scale was equivalent or superior to the other scales at
predicting incident ADL deficits, incident IADL deficits, and mortality at
9 years. Muscle mass in the frail was 62.32%, pre-frail 61.72%, and non-
frail 65.95% (F014.78, p<0.001; pre-frail versus non-frail p<0.001; frail
versus non-frail p<0.05). Fat mass in the frail was 37.68%, pre-frail 38.28%,
and non-frail 34.05%. We concluded that the FRAIL scale is an excellent tool
for identifying frailty. This research was supported by a grant from the
National Institute on Aging to Dr. D. K. Miller (R01 AG-10436).
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poor outcomes after 6 years in middle-aged African Americans
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The Society of Sarcopenia, Cachexia and Wasting Disorders (SCWD) has
defined sarcopenia with limited mobility as a person with a low appendic-
ular skeletal mass (ASM; height corrected, 2 SD below referent adult group
ages 20–30) and with a gait speed walk ≤1m/s or with a 6-min walk
distance less than 400 m. In the population-based African American Health
(AAH) study (N0998 at baseline/year 1), muscle mass and mobility were
evaluated in a clinical testing center in a subsample of N0319 persons (ages
52–68). Muscle mass was measured using dual energy x-ray absorptiometry
(Hologic QDR 4,500W; Hologic, Inc., Bedford, MA, USA) and mobility by
a 6-min walk test and 4-m gait walk test. Height corrected ASM (9.0±1.5 in
n0124 males, 8.3±2.2 in n0195 females) was computed as total lean
muscle mass in arms and legs (kilograms) divided by the square of height
(meters). The longitudinal association of low ASM (bottom 25% AAH
sample; <7.96 males and <7.06 females) and low ASM with limited
mobility (4-m gait walk≤1 m/s or 6-min walk<400 m) with poor
outcomes after 6-years was examined for mortality, activities of daily
living (ADLs), instrumental activities of daily living (IADLs), injurious
falls, and frailty. Sample size was not large enough to define sarcopenia
according to the SCWD definition. Longitudinal analyses with
J Cachexia Sarcopenia Muscle (2012) 3:51–68 63adjustments for age and gender showed that low ASM with limited
mobility was associated with increased mortality (p00.003), the pres-
ence of one or more ADL disabilities (p00.059; marginal significance),
the presence of one or more IADL disabilities (p00.030), and with
frailty (p00.037) but not with injurious falls (p00.235). Low ASM
alone was marginally associated with mortality (p00.085) but not with
any other outcomes (all ps≥0.10). We concluded that low ASM with
limited mobility is a robust predictor of poor outcomes among African
Americans. This research was supported by a grant from the National
Institute on Aging to Dr. D. K. Miller (R01 AG-10436).
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Plasma levels of acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to
total ghrelin change in female inpatients with restricting-type anorexia
nervosa after treatment
Masako Nakano, Marie Amitani, Ken-Ichiro Koyama, Miho Uehara, Miharu
Ushikai, Akihiro Asakawa, Akio Inui (Division of Psychosomatic Internal
Medicine, Department of Social and Behavioral Medicine, Kagoshima Uni-
versity Graduate School of Medical and Dental Sciences, Kagoshima, Japan)
Anorexia nervosa (AN-R) is characterized by a restrictive eating pattern
resulting in severe weight loss, amenorrhea, and distorted perceptions of
body weight and shape. Associated psychopathology includes high levels
of anxiety and depression, low self-esteem, and interpersonal and familial
difficulties. Physical health is also severely compromised due to malnutri-
tion. In patients with AN-R, plasma ghrelin levels were reported to be
higher compared with normal-weight control subjects, reflecting a negative
energy balance of affected individuals. However, the early progress of these
patients and changes in the levels of acyl ghrelin and des-acyl ghrelin
during treatment were not reported. The purpose of this study was to
determine the changes on ghrelin levels (acyl and des-acyl) during early
treatment. A total 15 women participated in the study; 5 patients with AN-R
and 10 age-matched healthy controls. As a result, des-acyl ghrelin in
AN-R patients is higher than control subjects before therapy, but it is
decreasing with treatment. The plasma des-acyl ghrelin in AN-R
patients started decreasing more rapidly and in early stage of the
hospitalization than ever reported, and after 8 weeks, it is significantly
lower than in control subjects. It means that des-acyl ghrelin is sensi-
tive and changeable with their nutrition state. Furthermore, the ratio of
acyl ghrelin to total ghrelin is increasing with 8-weeks treatment. These
findings may be useful for developing anti-AN drug which increase the
ratio of acyl ghrelin to des-acyl ghrelin.
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Background and aims: Pro-inflammatory cytokines are important media-
tors in chronic diseases and cachexia development. Skeletal muscle actively
participates in cytokine production. Tumor necrosis factor (TNF)-alpha is
one of the major inflammation promoters with a central role in sepsis
development and chronic diseases progression. Statins have beneficial
anti-inflammatory effects and are widely prescribed. We examined TNF-
alpha production in human myotubes and the effect of atorvastatin (AT) on
constitutive and lipopolysaccharide (LPS)-stimulated TNF-alpha secretion
with regard to AT concentration and time-of-exposure.
Methods: Human myotubes were exposed to different AT concentrations
ranging from sub- to supratherapeutic (0.1, 1, 10, 100 μM). AT exposure was
combinedwithtime-dependant LPS (100 ng/mL) exposure (no exposure,
48-h co-exposure,24-h pre-exposure,12-hpostexposure) to evaluate for time-
of-exposure effects.Constitutive and LPS-inducedTNF-alpha production was
observed. TNF-alpha concentration was measured using ELISA.
Results: Constitutive TNF-alpha levels were 9.78±1.03 pg/10.000 nuclei.
After exposing myotube cultures to increasing AT concentrations, no effect
on TNF-alpha secretion was observed. LPS stimulated TNF-alpha secretion
(9.8 vs. 24.5 pg/10,000 nuclei; p<0.01). After co-exposing myotube cul-
tures to LPS and AT, inhibitory effect of AT on LPS-induced TNF-alpha
secretion was observed, as well as in cultures pre-exposed to LPS before
treatment with AT. However, when myotube cultures were first treated with
AT and followed by LPS-exposure controversial stimulatory dose depen-
dent effect of AT on TNF-alpha secretion was observed.
Conclusions: AT does not affect constitutive TNF-alpha secretion in cul-
tured human myotubes, but inhibits LPS-stimulated secretion. Controver-
sial pro-inflammatory ATeffect was observed in pre-treatment prior to LPS,
suggesting a complex AT effects and involvement of different molecular
pathways. Concentration and time-of-exposure seem to be of great impor-
tance when considering statin-induced effects on TNF-alpha production.
7–18
Treatment of cancer cachexia-induced cardiomyopathy
AnikaTschirner
1,2, Jochen Springer
1,2, Sandra Palus
1,2, Josep Argiles
3,
Denise Hilfiker-Kleiner
4, Thomas Force
5, Stephan von Haehling
1,2, Stefan
D. Anker
2,6 (
1Center for Cardiovascular Research;
2 Applied Cachexia
Research, Department of Cardiology, Charité Medical School, Berlin,
Germany;
3Department of Biochemistry and Molecular Biology of Cancer,
University of Barcelona, Spain;
4Department of Cardiology and Angiology,
Medical School Hannover, Germany;
5Center for Translational Medicine,
Thomas Jefferson University, Philadelphia, USA;
6Centre for Clinical and
Basic Research, IRCCS San Raffaele, Rome, Italy)
Background: The AH-130 Yoshida hepatoma causes a severe cachexia in
rats, which then leads to the development of cardiomyopathy. Hence, we
wanted to investigate if treatment of tumor-bearing rats with cardiovascular
drugs can improve survival, body wasting and heart function.
Study design and methods: We used the AH-130 hepatoma model to
induce cachexia in male rats. We assessed body weight and body compo-
sition at begin (day 0) and end of the study (day 16). On day 1 we
inoculated the rats with 100×10
6 AH-130 cells and started daily with the
cardiovascular medication (bisoprolol, spironolactone, imidapril).
64 J Cachexia Sarcopenia Muscle (2012) 3:51–68Furthermore, we analysed the cardiac function and quality of life on days 0
and 10/11. After sacrificing the rats, we measured the weight of the organs
and tested the heart for atrophic mechanisms (UPS-system, caspases) and
anabolic signaling (Akt pathway).
Results: Treatment of tumor-bearing rats with bisoprolol or spirono-
lactone ameliorated body wasting by maintaining lean and fat mass.
Furthermore, these rats had an improved heart function compared to
the placebo group and a better survival (Biso: HR 0.32, p00.0017,
Spiro: HR 0.31, p00.0007). We could confirm the results by showing
less protein degradation and more protein synthesis by treatment
(increased activity of Akt, p70S6K). Treatment with imidapril was
not beneficial.
Conclusion: The Yoshida hepatoma animal model as a model for cancer
cachexia impaired severely the cardiac function and led to body and cardiac
wasting. Treatment of cancer cachexia with cardiovascular drugs improved
outcome.
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mRNA expression signatures of human skeletal muscle atrophy iden-
tify a natural compound that increases muscle mass
Steven D. Kunkel
1,2,3,5, Manish Suneja
2, Scott M. Ebert
1,2,3,K a l eS .
Bongers
1,2,3,D a n i e lK .F o x
1,2,3, Michael C. Dyle
1,2,3, Richard K. Shields
4,
Christopher M. Adams
1,2,3,5 (
1Fraternal Order of Eagles Diabetes Research
Center, The University of Iowa, Iowa City, IA 52242, USA;
2Department of
Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, The
University of Iowa, Iowa City, IA 52242, USA;
3Department of Molecular
PhysiologyandBiophysics,RoyJ.andLucilleA.CarverCollegeofMedicine,
The University of Iowa, Iowa City, IA 52242, USA;
4Department of Physical
Therapy, Roy J. and Lucille A. Carver Collegeof Medicine,The University of
Iowa, Iowa City, IA 52242, USA;
5Department of Veterans Affairs Medical
Center, Iowa City, IA 52246, USA)
Skeletal muscle atrophy is a common and debilitating condition that lacks a
pharmacologic therapy. To develop a potential therapy, we identified 63
mRNAs that were regulated by fasting in both human and mouse muscle,
and 29 mRNAs that were regulated by both fasting and spinal cord injury in
human muscle. We used these two unbiased mRNA expression signatures
of muscle atrophy to query the connectivity map, which singled out ursolic
acid as a compound whose signature was opposite to signatures of muscle
atrophy. A natural triterpene acid, enriched in apple peels, and ursolic acid
reduced muscle atrophy in three distinct mouse models: fasting, denerva-
tion, and immobilization. Moreover, when administered to mice in the
absence of an atrophy-inducing stress, ursolic acid stimulated muscle hy-
pertrophy and increased grip strength. We found that ursolic acid reduced
atrophy and stimulated hypertrophy by enhancing skeletal muscle insulin/
IGF-I signaling and inhibiting atrophy-associated mRNA expression.
Importantly, ursolic acid’s effects on muscle were accompanied by reduc-
tions in adiposity, fasting blood glucose, and plasma cholesterol and trigly-
cerides. These findings identify a potential therapy for muscle atrophy and
perhaps other metabolic diseases. This work was supported by the Doris
Duke Charitable Foundation, NIH, the Department of Veterans Affairs, the
University of Iowa Institute for Clinical and Translational Science and the
University of Iowa Research Foundation.
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Tissue-protective effect of the non-hematopoetic erythropoietin
analogues ARA284 and ARA286 in the treatment of cancer
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Table 1. Cardiovascular treatment in cancer cachexia
Sham (n016) Placebo (n073) Bisoprolol, 5 mg/kg/day (n023) Spironolactone, 50
mg/kg/day (n016)
Δ Body weight [g] 59.8±2.1 *** −53.7±1.77 −21.9±10.55 *** −21.0±11.03 ***
Δ Fat mass [g] 9.11±0.90 *** −12.35±0.36 −5.86±1.87 *** −6.70±2.13 ***
Δ Lean mass[g] 41.7±2.03 *** −39.8±1.56 −16.71±7.68 *** −11.86±8.69 ***
Food intake day 11 [g/24 h] 21.3±0.84 *** 4.30±0.48 10.93±2.01 *** 9.81±1.73 **
Activity day 11 (counts/24 h) 67,192±2,847 *** 29,509±1,775 43,755±3,741 ** 44,817±5,286 **
LV Ejection fraction [%] 72.8±2.34 *** 51.9±1.99 57.1±4.11 65.9±3.48 **
Fractional shortening 51.6±1.53 *** 30.8±1.57 32.3±3.47 42.8±2.6 **
Δ LV mass [mg] 110±29.1 *** −101±14.18 −4.52±31.2 ** 37.9±12.03 ***
Trypsin-like activity of the heart
[nmol/mg protein /min]
488±95.9 ** 1,094±118 805±46.1 * 762±7.87 *
Activity of caspase-3 in the heart
[nmol/mg protein/min]
35.6±4.453 *** 82.9±10.70 60.2±9.01 40.8±10.23 *
LV left ventricular
*p<0.05, **p<0.01, ***p<0.001 vs placebo
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Background: Cancer cachexia is a syndrome characterized by significant
loss of muscle and fat tissue. Therefore searching for the compounds
protecting tissue during cachexia is of current interest. Erythropoietin
(EPO) was shown to be effective in tissue protection, but has side effects
like hematopoesis. The aim of our research was to investigate the protective
effect of two non-hematopoetic EPO analogues ARA284 and ARA286 on
rat tissues during cancer cachexia.
Methods: Young male Wistar Han rats were inoculated with 10
8 Yoshida
AH-130 hepatoma cells and treated with 500 or 5,000 U/kg/day EPO or the
equivalent dose of the tissue-protective molecules (TPM) ARA284 and
ARA286 (0.17 or 1.7 μg/kg/day, respectively). Body weight and body
composition were analyzed before the initiation of experiment and after
sacrifice and removal of the tumour on day 16. Organs were weighted and
stored at −80.
Results: It was shown that ARA284 and ARA286 in high doses (HD)
significantly reduced weight loss in comparison with placebo group (p0
0.0058). The loss of fat mass was attenuated (p00.027) as well as preser-
vation of epididymal fat (p00.003) and protection of lean mass (p00.012)
compared to placebo. The weight of gastrocnemius muscle increased (p0
0.015) in HD groups and at the same time the levels of biochemical markers
of cachexia improved in these samples. Thus, the levels of phosphorylated
p38 MAPK and activated myostatin were significantly decreased (p<0.05)
in both HD groups, amount of GSK-3β and Akt significantly changed (p<
0.05)inARA286group.Low-doseARA284alsoprotectedthetissues,buttoa
lesser extent than high dose. ARA286 in low concentration had no effect. No
effect was observed on survival using TPMs.
Conclusions: ARA284 and ARA286 were shown to be effective in reduc-
ing tissue wasting in rat cancer cachexia model. These compounds should
be seen as prospective drugs for human cancer cachexia.
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Background: Sarcopenia, an age-related progressive loss of skeletal mus-
cle mass, strength and function, would be a more relevant future health
issue within the next years. There are no efficient pharmacological inter-
ventions to counteract effects of sarcopenia.
Methods: Body weight and body composition (NMR-scan) of 19-month-
old male Wistar Han rats (weight approximately 555 g) were analysed 1 day
before starting treatment with 3.0 mg/kg/day MT-102 or placebo as well as
once a week of the 31-day protocol. Quality of life parameters (food and
water intake, spontaneous activity) were determined 1 day before treatment
started and on day 28. Proteasome and caspase activities were measured by
a kinetic turnover of fluorogenic substrates. Proteins involved in anabolic
and catabolic signalling were analysed by Western blot.
Results: Aged rats lost body weight (−15.5±7.2 g), lean mass (−1.5±4.2 g)
and fat mass (−15.6±2.7 g). Food intake was unchanged (+0.66±0.8 g), water
intakewasdecreased(−1.7±1.4ml)comparedtobaseline.Animalstreatedwith
3.0 mg/kg/day MT-102 gained body weight (+8.0±6.1 g, p<0.05) and partic-
ularly lean mass (+43.4±3.5 g, p<0.001), leading to increased weight of
skeletal muscle and heart. Interestingly, animals lost more fat mass compared
to placebo (−38.6±3.4 g, p<0.001). Food (+4.8±1.5 g, p<0.01) and water
(+2.6±1.9 ml, p<0.05) intake could be increased by 3.0 mg/kg/day MT-102
compared to baseline. A decrease in proteasome and caspase-6 activity was
observed by 3.0 mg/kg/day MT-102. FoxO3a and NFkB (p<0.01), key regu-
lator proteins for catabolic signalling, were less expressed, confirmed by less
expression of E3-ligases MuRF-1 (p<0.01) and atrogin-1 (p<0.01). Myostatin
w a sl e s se x p r e s s e d( p<0.001), leading to an increase in MyoD expression (p<
0.01). A reduction in autophagy was observed, indicated by a decreased LC3-II
protein expression (p<0.001) and a higher LC3-ratio (p<0.001).
Conclusions: MT-102 (3.0 mg/kg/day) reversed effects of ageing, especial-
ly loss of muscle mass and increased fat mass. Hence, it is likely to be also a
prospective drug to treat patients suffering from sarcopenia.
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Background: MT-102 is being developed to reverse effects of cancer
cachexia. The pharmacological profile includes anabolic effects on
skeletal muscle, inhibition of lipolysis, stimulation of appetite and
reduction in energy expenditure. MT-102 is currently in a phase II
clinical trial for treatment of cancer cachexia due to Stage III or IV
colorectal cancer or non-small cell lung cancer.
Methods: Young male Wistar Han rats (approximately 200 g) were intra-
peritoneally inoculated with 10
8 Yoshida AH-130 hepatoma cells. Animals
were treated once a day with 0.3 or 3.0 mg/kg MT-102 or placebo. Body
weight and body composition (NMR-scan) were analysed 1 day before
tumour-inoculation and after sacrifice. Proteasome and caspase activities
were measured by a kinetic turnover of fluorogenic substances. Proteins
involved in anabolic and catabolic pathways were analysed by Western blot.
Results:Apreventionoflosingbodyweight(−0.9±13.1gvs.placebo−53.7±
1.8 g; p<0.001) and fat mass (−5.87±2.02 g vs. placebo −12.35±0.36 g; p<
0.001) could be achieved by 3.0 mg/kg/day MT-102. Interestingly, 3.0 mg/kg/
66 J Cachexia Sarcopenia Muscle (2012) 3:51–68dayMT-102 ledto a gain of leanmass(+1.1±10.3 g vs. placebo −39.8±1.6 g;
p<0.001). Moreover, survival proportion was improved by 3.0 mg/kg/day
MT-102(HR00.29,0.16−0.91;p<0.0001).Proteasomeandcaspaseactivities
were not reduced. Expression of PI3K and Akt in a phosphorylated, activated
form was significantly upregulated (p<0.05 vs. placebo) by 3.0 mg/kg/day
MT-102, whereas expression of activated form of FoxO3a (p<0.01 vs. place-
bo) and FoxO1 (p<0.05 vs. placebo), key regulator proteins for catabolic
signalling, were significantly downregulated. Phosphorylated, activated form
ofNFkB(p<0.05vs.placebo)andSmad2(p<0.001vs.placebo)andactivated
form of GSK3a (p<0.05), proteins involved in catabolic signalling, were
significantly less expressed. Autophagic activity was reduced, indicated by a
lower expression of LC3-II protein (p<0.001vs.placebo).
Conclusions: MT-102 (3.0 mg/kg/day) implicates a pro-anabolic and anti-
catabolic effect, resulting in a gain of lean mass. Importantly, survival was
significantly improved in this animal model of severe cancer cachexia.
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Background: Cancer cachexia is associated with impairment in heart func-
tion, caused by a progressive loss of heart weight due to a pathologic decrease
insizeandmass.Atrophyofepicardiumwithmarkeddiminutionandtherefore
loss of epicardial fat mass is also described, as well as increased pigmentation
of myocardium and little or no alteration of endocardium.
Methods: Young male Wistar Han rats (weight approximately 200 g) were
intra-peritoneally inoculated with 10
8 Yoshida AH-130 hepatoma cells.
Animals were treated once a day with 0.3 or 3.0 mg/kg MT-102 or placebo.
Echocardiography of heart was determined 1 day before tumour-inoculation
and on day 11 of the 16-day protocol. Body weight and body composition
(NMR-scan) were analysed 1 day before tumour-inoculation and after
sacrifice.
Results: Heart weight was significantly increased in the group treated with
3.0 mg/kg/day MT-102 (573±32 mg vs. placebo 506±8 mg; p<0.001). Heart
rate was not significantly affected by 3.0 mg/kg/day MT-102 (326±12 bpm),
or 0.3 mg/kg/day MT-102 (327±18 bpm) compared to placebo (366±
13 bpm). Left ventricular ejection fraction (64.06±2.50% vs. placebo 51.91
±1.99%;p<0.01)andfractionalshortening(38.91±2.84%vs.placebo30.75±
1.57%; p<0.05) were likely to be significantly improved by high dose of MT-
102, as well as stroke volume (175.30±16.67 μl vs. placebo 104.93±6.93 μl;
p<0.001). Left ventricular end-diastolic diameter was significantly larger in
both treated groups (0.3 mg/kg/day MT-102, 6.40±0.12 mm; 3.0 mg/kg/day
MT-102, 6.27±0.14 mm vs. placebo 5.71±0.11 mm; p<0.05), but close to
sham level (6.39±0.08 mm). Left ventricular end-diastolic volume was also
significantly increased by 3.0 mg/kg/day MT-102 (265.3±17.3 μlv s .
placebo 196.6±9.8 μl; p<0.05) and with it close to sham level
(269.18±10.77 μl).
Conclusions: A daily dose of 3.0 mg/kg MT-102 reversed impaired heart
function and stopped cardiac wasting seen in placebo animals in this animal
model of cancer cachexia. Hence, it is a prospective drug to treat patients
suffering from cancer cachexia particularly if patients show signs of declined
cardiac function. Currently, MT-102 is in a phase II cancer cachexia trial.
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Background and aims: Stem cell therapy is a potential approach to treat
loss of skeletal muscle observed in cachexia. Vascular stromal fraction of
adipose tissue represents an abundant and accessible source of pluripotent
cells that can differentiate into several cell types including myogenic cells.
In vitro studies have shown that mature adipocytes are capable of dediffer-
entiating into proliferating fibroblast-like cells. Dedifferentiated fat (DFAT)
cells can differentiate, upon appropriate treatments, into skeletal myocytes.
The final aim of this project is to study the myogenic potential of human
DFAT cells in a mouse model of cachexia evaluating their contribution to
regenerate skeletal muscle tissue.
Methods: We used the ceiling culture method to obtain DFAT cells from
human adipose tissue. DFATcells gene expression was analysed by RT-PCR.
Moreover, we labelled DFAT cells with nuclear GFP using a lentiviral trans-
duction system.
Results: We analysed the gene expression profile of DFAT cells in order to
characterise their stemness and myogenic potential. To investigate the
ability of human DFAT cells to fuse with myocytes in co-culture, we
validated a GFP-labelling method based on lentiviral transduction system.
Moreover, we plan to improve the myogenic potential of DFAT cells by
lentiviral-mediated forced expression of MyoD in vitro.
Conclusions: WeproposetoevaluatethemyogenicpotentialofhumanDFAT
cells in muscle engraftment approaches in a mouse model of cachexia. In
summary, we suggest DFAT cells as a potential novel promising source of
pluripotent cells available for a new cell therapy approach designed to treat
cachexia.
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Background and aims: The proinflammatory cytokine interleukin-1α
plays an important role in anorexia–cachexia syndrome. MABp1 is the first
true human monoclonal antibody against interleukin-1α. We determined the
effect of MABp1 on lean body mass, nutrition intake, and appetite among
advanced cancer patients.
Methods: This is an open-label, first-in-man, phase I trial of MABp1 in
patients with metastatic/refractory cancers. Patients were given MABp1 intra-
venously at one of four dose levels every 3 weeks. For anorexia–cachexia
assessment,wecollectedserialdatausingdual-emissionX-rayabsorptiometry
scan (DEXA), indirect calorimetry, daily nutrition diary, and EORTC QLQ-
C30. We compared our findings between baseline and cycle 3.
Results: Baseline characteristics of the 36 enrolled patients were: average age
60, female 20 (56%), colorectal malignancies 14 (40%), median weight 61 kg
(range 42–90 kg), median body mass index 24 kg/m
2, median resting energy
expenditure 1,915 kcal, and hypermetabolic 92%. MABp1 was well tolerated
with no infusion reactions and minimal adverse side effects. Twenty patients
completed three or more cycles, and were included in the anorexia–cachexia
analysis. Between baseline and cycle 3, the lean body mass increased by a
median of 0.32 kg by DEXA (range −1.4–6.9 kg, N017, P00.13). Lean body
mass change was not associated with tumor response. Median resting energy
expenditure remained similar to baseline. The daily average caloric intake
increased by a median of 178 kcal (range −985–1,017 kcal). EORTC-appetite
significantly improved (median change −33, P00.02). EORTC-global quality
of life improved in 7/20 (36%) and remained the same in 8/20 (40%) patients.
Conclusions: In this phase I study, MABp1 showed preliminary evidence
of improving lean body mass, nutritional intake and appetite despite the
high baseline hypermetabolic rate. MABp1 was well tolerated with minimal
adverse events. Further studies are needed to confirm our findings.
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Introduction: Cancers of the colon and rectum are the third most common
forms of cancer worldwide. The prognosis for survival after disease progression
is usually poor. Cancer anorexia–cachexia syndrome is prevalent among ad-
vanced cancer patients, and has a large impact on morbidity, mortality, and a
patient’s quality of life. Early intervention with nutritional supplementation has
been shown to halt malnutrition, and may improve outcome in some patients. In
our study, we assessed the influence of nutritional support (counseling, nutri-
tionalsupplements,andmegestrol acetate)onthenutritionalstatusandsymptom
prevalence in patients with colorectal cancer during chemotherapy. The study
was designed to investigate whether dietary counseling, oral nutrition (commer-
cial supplements), and megestrol acetate during chemotherapy affected nutri-
tional status and survival in patients with colorectal cancer.
Methods: Six hundred and twenty-eight colorectal cancer patients were
included in the study from January 2001 through December 2009, and
randomized into one of two groups. Group I consisted of 315 patients
(50%) who were monitored prospectively and were given nutritional sup-
port. Group II included 313 patients without nutritional counseling or
nutritional support, in whom data were collected prospectively during a 9-
year period of time. Patients were well balanced between the two groups.
After evaluation (Nottingham Screening Tool Score, Appetite Loss Scale,
and ECOG PS, weight), all patients in group I received nutritional counsel-
ing, oral nutritional food supplements, and megestrol acetate.
Results: After the completion of chemotherapy, there were lower propor-
tions of patients in group I with a BMI<20, NST≥5, loss of appetite, and
decreased weight gain. Nutritional counseling, supplemental feeding, and
pharmacological support temporarily halted weight loss and improved
appetite. This improvement may have implications for patient survival.
Patients with early nutritional support lived 19.1 months while patients in
the control group had a survival of 12.4 months (p00.022).
Conclusion: These results encourage further studies with more specific
nutritional supplementation in patients with colorectal cancer.
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